News Center

Technology

From the screening of cell lines to cell culture development, Henlius professional team make effort in maximizing output, while ensuring high quality of products. Our international standard laboratory is equipped with advanced equipment, and we make use of our abundant technical and scientific expertise to develop and optimize the production process...

2017 Company Memorabilia

  • 01
  • 02
  • 03
  • 04
  • 05
  • 06
  • 07
  • 08
  • 09
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
Henlius won the “Best Bioprocessing Excellence in China”and
"Leading Innovationgs in Cuttting-edge Technologies for Novel mAb Development & Production" awards at IMAPAC conference.
Henlius was named one of “Specialized, Sophisticated,
Distinctive and Innovative SMEs” by Shanghai Municipal Commission of Economy and Informatization.
HLX02 was approved for Phase III clinical trials in Ukraine,
being the first Chinese biosimilar product to conduct oversea clinical studies.
The clinical trial application of HLX06
for treatment of solid tumors was accepted for filing by the CFDA.
The clinical trial application of HLX10
for treatment of solid tumors was accepted for filing by the CFDA.
HLX01 (Rituximab) received the Drug Manufacturing Certificate
from the Shanghai Food and Drug Administration.
HLX02 successively received the approval for Phase III clinical trials
the other innovative product HLX06 officially submitted PCT invention patent application
HLX06 successively received the approvals
for treatment of solid tumors by FDA and TFDA.
HLX10 successively received the approvals
for treatment of solid tumors by FDA and TFDA.
HLX01 for treatment of non-Hodgkin’s Lymphoma (NHL)
was accepted for the new drug application (NDA) filing by CFDA, closing in the first domestic marketing biosimilar product in China.
HLX03 for treatment of psoriasis (PS) entered the Phase III clinical study.
Henlius was awarded “Caohejing Hi-tech Park Innovative Star”.
Henlius was honored as “2017 ZERO2IPO Venture 50”.
Henlius won the “2017 Deloitte China Rising Star of Medicine and Health” award.
Henlius has been honored “Life Science & Healthcare Unicorn Enterprise in China 2017”.
The clinical trial application of HLX20
for treatment of solid tumors was accepted for filing by the CFDA.
The clinical trials applications of HLX04 for two new indications of eye diseases was accepted by CFDA.
Henlius signed official investment agreement with Shanghai Songjiang District Government
to build a biologics manufacturing facility (II) in Songjiang District, Shanghai.
Henlius Proposed to raise shares of USD 190 million,
pushing the companys market capitalization to more than CNY 10 billion.

Career

In Henlius, employees are of overriding importance and talents are the most valuable assets for the company. We recognize talents and make the best of them through cultivation with professional trainings to retain them......

Recruiting Position